ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MD vs MRK // GROSS PROFIT MARGIN

Pediatrix Medical Group Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: MD 5 — MRK 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MD VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MD MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 33.60% 20.70% +12.90 MD /roic <GO>
EV/EBITDA & P/E Valuation 9.6x 15.3x -5.70 MD /valuation <GO>
Free Cash Flow Yield 11.43% 3.42% +8.01 MD /fcf-yield <GO>
Operating Margin — 34.30% — TIE /operating-margins <GO>
Net Profit Margin — 28.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 71.7 51.7 +19.97 MD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 13.3x 18.4x -5.10 MD /forward-pe <GO>
Enterprise Scale & Market Cap $2.37B $361.02B -$358.65B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MD REV MRK REV MD GROSS % MRK GROSS % MD FCF MRK FCF
FY 2025 $0 $65.01B — 74.8% $271.1M $12.36B
FY 2024 $0 $64.17B — 76.3% $206.6M $18.10B
FY 2023 $0 $60.12B — — $137.3M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MD // BETA —
MRK // BETA 0.92